How UnitedHealth Group Makes its Money: Revenue Breakdown (2024)

How Does UnitedHealth Group Make its Money?

UnitedHealth Group Incorporated (NYSE: UNH) generated $400.3 billion in total revenue in fiscal year 2024 — up +7.7% from $371.6B in 2023 — making it the largest healthcare company in the world by revenue and the 5th-largest company by revenue of any kind globally, behind only Walmart, Amazon, Saudi Aramco, and State Grid. By comparison, UnitedHealth’s $400B in revenue exceeds Apple ($391B), Berkshire Hathaway, and every US bank. The company serves 152 million people globally across health insurance, direct healthcare delivery, pharmacy benefits management, and healthcare data analytics.

UnitedHealth operates through two primary businesses: UnitedHealthcare — the health insurance arm covering 50+ million members across employer plans, Medicare Advantage, Medicaid, and international markets — and Optum — a diversified health services platform encompassing direct care delivery (90,000+ physicians), pharmacy benefit management (1.6B+ prescriptions/year), and data analytics/technology. The strategic architecture is a vertically integrated healthcare ecosystem: UnitedHealthcare sells insurance and collects premiums, then directs a growing share of member care through Optum-owned and Optum-affiliated physicians, Optum-managed pharmacies, and Optum-operated facilities — capturing value at each step of the healthcare continuum.

The financial story of 2024 was substantially complicated by two exogenous events: (1) the Change Healthcare cyberattack (February 2024) — one of the largest cyberattacks in US healthcare history, disrupting medical claims processing across virtually the entire US healthcare system for weeks and costing UnitedHealth $2.9B+ in remediation and direct losses; and (2) elevated medical cost utilization following COVID-19 pent-up demand, which pushed the Medical Cost Ratio (the percentage of premiums paid in claims) to 85.4% — higher than historical norms and creating margin pressure. Despite these headwinds, UnitedHealth grew revenue +7.7%, maintained net income of $22.4B, and continued expanding Optum’s strategic footprint.

Key Takeaways

• UnitedHealth generated $400.3B in 2024 revenue (+7.7% YoY) and $22.4B in net income — the 5th-largest revenue company in the world; the revenue figure is deceptive in scale comparison: much of it represents premium dollars collected by UnitedHealthcare and pass-through pharmacy drug costs via Optum Rx (which buys $130B+ in drugs and resells them); net income of $22.4B on $400B revenue = 5.6% net margin, which is typical for vertically integrated health insurers but low relative to standalone tech or pharma companies
• UnitedHealthcare (health insurance) is the revenue anchor at $298B — but this includes large intercompany eliminations; the insurance business covers 50M+ members across: Employer & Individual (commercial plans for large/small employers and ACA marketplace), Medicare Advantage (~29% US market share, the largest MA insurer), Medicaid (managed Medicaid programs in multiple states), and international (Brazil, Chile, and other markets); Medicare Advantage is the highest-strategic-priority growth segment, with the 65+ US population growing rapidly and MA penetration continuing to expand
• Optum is the strategic transformation story — a health services conglomerate growing faster than the insurance parent; Optum Health ($100.2B revenue, +7.4%), Optum Rx ($131.2B, +12.9%), and Optum Insight ($20B, +7.5%) collectively represent the vertical integration layer that differentiates UnitedHealth from pure-play insurers; Optum’s operating margins (~8–9%) are meaningfully higher than the insurance-only model because service businesses generate revenue beyond the insurance premium cycle
• Medical Cost Ratio (MCR) of 85.4% — the most critical metric for health insurer profitability; MCR = medical claims paid ÷ premium revenue; at 85.4%, UnitedHealthcare retains 14.6 cents of every premium dollar to cover operating expenses and profit; MCR rose in 2024 due to higher-than-expected utilization (post-COVID catch-up care, behavioral health demand surge, and outpatient volume increases) and the Change Healthcare disruption; management’s target range is 83.5–84.5%; MCR compression back to that range is the primary near-term earnings catalyst
• Change Healthcare cyberattack — In February 2024, Russian-linked cybercrime group ALPHV/BlackCat attacked Change Healthcare (a UnitedHealth subsidiary handling ~50% of US medical claims processing); the attack took Change Healthcare offline for weeks, disrupting billing and payments for hospitals, physicians, and pharmacies nationwide; UnitedHealth advanced $6B+ in loans to affected providers and spent $2.9B+ in direct cyberattack response costs; the incident exposed the systemic concentration risk in US healthcare IT infrastructure and triggered Congressional scrutiny; UnitedHealth paid a $22M ransom to recover encrypted data (which was reportedly still leaked by the attackers)
• Vertical integration regulatory risk — UnitedHealth’s ownership of insurance + care delivery + pharmacy benefits + data analytics creates what critics call an inherent conflict of interest: UnitedHealthcare (the insurer) has financial incentives to deny or delay care claims, while directing members to Optum-affiliated providers (which generates additional revenue for UnitedHealth); the FTC, DOJ, and multiple state attorneys general have investigated UnitedHealth’s vertical integration; any forced structural separation of UHC and Optum would be the most significant negative event for UNH shareholders in the company’s history
• CEO transition and market cap collapse — In December 2024, UnitedHealth CEO Brian Thompson was killed outside a New York hotel in a targeted shooting; the incident triggered extraordinary public discourse about health insurance industry practices (claim denial rates, prior authorization policies, MCR-driven coverage limitations); the company’s stock also experienced significant volatility in 2025 amid DOJ investigations into Medicare Advantage billing practices and elevated medical cost concerns; the stock fell from ~$600 to below $300 in 2025, roughly halving the company’s market cap

UnitedHealth Group (UNH) Business Model

UnitedHealth operates a vertically integrated healthcare ecosystem — combining insurance risk management with direct care delivery and pharmacy services under one corporate umbrella. See the Healthcare Sector for industry context and the Platform Ecosystem Business Model for the structural framework.

The vertical integration logic:

Traditional health insurance is a single-margin business: collect premiums, pay claims, keep the spread. UnitedHealth’s strategic insight is that by owning the care delivery and pharmacy layers as well, it can: (1) capture additional revenue per member on care services and pharmacy; (2) influence care protocols to reduce unnecessary utilization (improving MCR); (3) collect data from clinical encounters that improves risk scoring and actuarial accuracy; (4) create switching costs that make employer clients and members more embedded in the UnitedHealth ecosystem.

The model in practice:

Medicare Advantage — the highest-priority growth segment:

Medicare Advantage (MA) is the private alternative to traditional Medicare for Americans 65+. Instead of going directly to the federal government for Medicare, a senior enrolls with a private insurer like UnitedHealthcare, which receives a fixed monthly payment from the federal government (the “capitation rate”) per member and manages the member’s healthcare. UHC’s MA economics:

• ~29% US market share of Medicare Advantage — the single largest MA insurer; approximately 8–9 million Medicare Advantage members
• Revenue per MA member: ~$1,200–1,400/month (the CMS capitation rate varies by member health risk score and geography)
• Profitability: MA is typically the most profitable insurance product for carriers when MCR is managed well — the capitation model allows more revenue certainty than commercial insurance
• Growth driver: 10,000 Americans turn 65 every day; MA enrollment has grown from ~13% of Medicare (2003) to ~55% (2024) and is continuing to grow; MA members represent a growing share of UHC’s enrollment and revenue

Optum Rx and PBM economics:

Pharmacy Benefit Management (PBM) is one of the most opaque and scrutinized businesses in US healthcare. Optum Rx is the third-largest PBM alongside CVS Caremark (CVS Health) and Express Scripts (Cigna/Evernorth). PBMs:

• Negotiate drug prices with pharmaceutical manufacturers — drug makers offer “rebates” to PBMs in exchange for favorable formulary placement (the drug appearing on the preferred coverage list)
• Process claims between pharmacies, insurers, and manufacturers
• Operate mail-order and specialty pharmacies that dispense drugs directly to members
• Earn revenue from spread pricing (charging the health plan more than they pay the pharmacy), dispensing fees, and retained rebates

Optum Rx processed approximately 1.6 billion prescriptions in 2024 and managed pharmacy benefits for most UnitedHealthcare members plus external health plan clients. The PBM business is under intense regulatory pressure: Congress, state legislatures, and the FTC have all investigated PBM practices and proposed legislation to mandate rebate pass-through and eliminate spread pricing.

UnitedHealth Group Competitors

Health insurance:

• CVS Health — CVS’s Aetna insurance arm is UnitedHealth’s most direct competitor, combined with CVS’s pharmacy (retail + PBM/Caremark) vertical integration; CVS’s model mirrors UnitedHealth’s in structure (insurance + pharmacy benefits + retail pharmacy) but at smaller scale (~$370B total CVS revenue); Aetna covers ~35–36M members vs. UHC’s 50M+; see the CVS Health page for the comparative financial analysis
• Elevance Health — formerly Anthem; the second-largest pure health insurer by membership (~45M members); primarily commercial and Blue Cross/Blue Shield-affiliated plans with significant Medicaid managed care; Elevance’s IngenioRx PBM and Carelon health services division mirror UnitedHealth’s Optum strategy at smaller scale; Elevance has been more aggressive in Medicaid expansion than UHC
• Humana — approximately 16–17M members with heavy concentration in Medicare Advantage; Humana is the #2 MA insurer behind UHC; CenterWell (Humana’s care delivery division) is a direct analog to Optum Health; Humana has faced the same elevated MCR pressures as UHC in 2024–2025
• Cigna/Evernorth — Cigna’s insurance and Evernorth (health services, including Express Scripts PBM) is the closest structural analog to UnitedHealth’s dual business model; Express Scripts is the second-largest PBM; Cigna has been focused on profitable growth rather than MA market share expansion

Healthcare services (Optum competitors):

• HCA Healthcare — the largest for-profit hospital system; competes with Optum Health in outpatient and ambulatory care; HCA’s shift to outpatient care delivery competes with Optum-affiliated physician groups and ambulatory surgery centers for the same patient volumes
• Johnson & Johnson — competes with Optum in the medical technology and pharmaceutical segments; not a direct insurance competitor but J&J’s MedTech division competes for procedure revenue that flows through UnitedHealth’s insurance claims
• Eli Lilly and Pfizer — pharmaceutical manufacturers whose drug pricing is negotiated by Optum Rx through the PBM; the pharmaceutical manufacturer vs. PBM pricing tension is a defining structural conflict in US healthcare economics; GLP-1 drugs (Mounjaro, Zepbound from Eli Lilly; Ozempic, Wegovy from Novo Nordisk) are creating significant new cost pressures for health insurers including UHC as member demand for weight-loss drugs grows

For insurance-to-health-services integration comparisons, see JPMorgan vs Bank of America for a parallel vertical integration analysis in financial services.

Revenue Breakdown

Note: The eliminations ($148.5B) primarily represent Optum services delivered to UnitedHealthcare members — revenue counted in both UHC (as premium) and Optum (as service revenue) is eliminated at consolidation. The “true” external revenue is substantially lower — the $400B headline includes significant internal transactions.

Financial data sourced from UnitedHealth Group 2024 Annual Report (10-K).

UnitedHealthcare — $298B Gross Revenue (5.9% YoY)

UnitedHealthcare’s 50M+ member base breaks down across four product lines:

Employer & Individual (~27M members): Commercial health plans for large employers (self-funded plans, where UHC administers benefits but the employer bears the medical risk), fully insured group plans for smaller employers, and individual/ACA marketplace plans. Large employer self-funded plans are particularly valuable because UHC earns administrative fees without bearing medical cost risk — pure fee revenue at relatively high margins.

Medicare Advantage (~8–9M members): UHC’s largest MA membership at ~29% market share. Each MA member generates $1,200–1,400/month in capitation from CMS, adjusted upward for sicker/higher-risk members via a risk adjustment process. MA is the highest-growth segment: 10,000 Americans turn 65 daily, and MA’s penetration of all Medicare eligibles continues rising (55%+ in 2024). The 2024 and 2025 challenges: CMS reduced MA payment rates in 2024 (cutting ~3.5% on risk-adjusted basis) while utilization rose — a simultaneous revenue compression and cost increase that drove MCR toward 90%+ in MA specifically.

Medicaid (~8–9M members): Managed Medicaid contracts where states pay UHC a fixed per-member rate to manage Medicaid populations. Profitability is lower than MA but the scale is large. Multiple states are re-procuring Medicaid contracts — UHC wins and loses state contracts regularly, creating quarterly enrollment volatility.

International (~5M members): Operations in Brazil, Chile, Peru, and other markets. Growing but small relative to domestic operations.

Optum Health — $100.2B (7.4% YoY)

Optum Health is the direct care delivery arm — employing or closely affiliating with 90,000+ physicians across primary care, specialty, behavioral health, home health, and ambulatory surgery. Revenue comes primarily from:

• Capitated care arrangements: Fixed monthly per-member payments from health plans (including UnitedHealthcare) for Optum-affiliated physicians to manage all care; the Optum physician takes on actuarial risk within their panel
• Fee-for-service: Traditional per-visit or per-procedure billing for care delivered to patients outside capitated arrangements
• Home health: Through Landmark (home visits for complex patients) and other home health platforms
• Behavioral health: Mental health and substance use disorder treatment — a rapidly growing and underpaid segment of US healthcare

The strategic value of Optum Health is control over clinical protocols: when Optum-affiliated physicians follow evidence-based care guidelines that reduce unnecessary procedures, hospitalizations, and readmissions, the MCR of UnitedHealthcare members who see Optum physicians improves. The insurer and the care deliverer have aligned financial incentives — the opposite of the traditional fee-for-service model where physicians earn more by ordering more tests and procedures.

Optum Rx — $131.2B (12.9% YoY)

Optum Rx is the second-largest pharmacy benefit manager by prescription volume. The +12.9% growth reflects: (1) organic prescription volume growth as more UHC members use Optum Rx as their PBM; (2) drug price inflation passing through the P&L on a gross basis (PBMs pass drug costs through to health plans, inflating both revenue and cost); (3) growing specialty pharmacy volume (high-cost drugs for cancer, autoimmune diseases, GLP-1 weight-loss drugs).

GLP-1 drug cost challenge: GLP-1 agonists (Ozempic, Wegovy from Novo Nordisk; Mounjaro, Zepbound from Eli Lilly) for obesity and diabetes cost $800–1,200/month per member. As employer plans and Medicare Advantage programs consider covering these drugs, the cost per covered member increases substantially. Optum Rx negotiates rebates from Eli Lilly and Novo Nordisk, but even after rebates, GLP-1 coverage represents a significant MCR risk for UHC as the insurer.

Optum Insight — $20.0B (7.5% YoY)

Optum Insight is the healthcare data and technology division. Revenue comes from:

• Revenue cycle management: Software and services that help hospitals and physician groups bill, code, and collect payment; this was the Change Healthcare business (now recovering post-cyberattack)
• Clinical analytics: AI tools for identifying high-risk members before they become expensive, suggesting preventive interventions
• Population health management: Data platforms for health systems to manage patient outcomes at a population level
• EHR/IT services: Integration with electronic health records, connectivity between payers, providers, and pharmacies

Optum Insight’s ~20%+ operating margin (the highest of any UNH segment) reflects the software and data nature of the business — once the platform is built, incremental revenue carries high margins.

Revenue Trend (3-Year)

The MCR trend (82.0% → 83.3% → 85.4%) is the critical warning signal embedded in the three-year data: medical costs are rising faster than premiums, compressing the insurance margin. The improvement to 83.5–84.5% MCR that management targets for 2025–2026 is achievable but requires: CMS MA rate improvements, premium repricing to match elevated cost trends, and continued Optum clinical integration reducing unnecessary utilization.

UnitedHealth Group (UNH) Income Statement

Financial data sourced from UnitedHealth Group SEC filings.

Medical costs grew +8.5% vs. revenue +7.7% — this 80bps gap is the core margin compression story; medical cost growth outpacing premium growth is the defining challenge for UNH in 2024–2025; every 10bps of MCR increase on a $254B claims base = ~$254M in additional claims expense.

Change Healthcare cyberattack costs of $2.87B — a significant one-time charge that reduced 2024 net income; excluding this, net income would have been approximately $25B+; management has characterized most of this as non-recurring, though ongoing legal liability from the breach remains uncertain.

Diluted EPS flat at $23.86 — net income essentially flat (+0.2%) despite revenue growing +7.7%; the gap is explained by MCR elevation and cyberattack costs; normalized EPS excluding cyberattack impact would have been approximately $26–27.

UnitedHealth Group (UNH) Key Financial Metrics

• Medical Cost Ratio (MCR): 85.4% — The single most important metric for health insurer profitability; MCR measures what percentage of premium revenue is paid out in medical claims; UHC’s target range is 83.5–84.5%; the elevation to 85.4% in 2024 reflects both genuine utilization increases and Medicare Advantage-specific pressures (CMS rate cuts + utilization spike); every 100bps of MCR improvement returns approximately $2.5B to operating income

• Gross Margin — The gross margin concept for health insurers is better captured by the “medical margin” (1 - MCR) = 14.6% of premiums retained before operating expenses; this is structurally low relative to other sectors but predictable at scale; Optum’s service businesses carry meaningfully higher gross margins (~30–40% for Optum Health, ~60%+ for Optum Insight) that blend upward as Optum grows

• Operating Margin: 7.6% — Thin by cross-sector comparison but typical for diversified health insurers at this scale; the operating margin reflects the blended result of low-margin insurance + higher-margin Optum services; as Optum grows as a share of total earnings, consolidated operating margins should expand structurally over time regardless of insurance MCR fluctuations

• Free Cash Flow — UnitedHealth generates approximately $20–23B in annual free cash flow — one of the highest absolute FCF figures of any US company; this FCF funds: an active dividend ($8.50+/share/year, ~$8B annually), substantial share buybacks ($5–8B/year), and strategic acquisitions (Optum has grown substantially through acquisitions of care delivery groups, physician practices, and technology companies); the FCF generation is remarkably stable because premium revenue is contractually recurring and medical cost trends, while variable, are actuarially predictable at scale

• Return on Equity — UnitedHealth’s ROE has historically been 25–30%+ — very high for a company of its size — reflecting both earnings power and the judicious use of financial leverage; the company carries meaningful long-term debt (~$60B+) used to fund share buybacks and acquisitions at a cost of capital below its business ROIC

The Change Healthcare Cyberattack: Full Impact

The February 21, 2024 cyberattack on Change Healthcare deserves detailed treatment because it is the most consequential event in US healthcare IT history and directly affected UnitedHealth’s 2024 financials:

What happened: ALPHV/BlackCat, a Russian-linked ransomware group, breached Change Healthcare’s systems through stolen Citrix credentials (no multi-factor authentication was enabled on the system). Change Healthcare processes approximately 50% of all US medical claims — an extraordinary single point of failure for the national healthcare system. The attack took Change Healthcare offline for weeks.

Systemic impact: Hospitals and physician practices nationwide couldn’t submit claims or receive payments; pharmacies couldn’t process prescriptions; UnitedHealth advanced $6B+ in emergency loans to affected providers to keep cash flowing through the healthcare system. The American Hospital Association estimated providers lost $1B+ per day in cash flow during the disruption.

UnitedHealth’s costs:

• Direct cyberattack response/remediation: $1.7B
• Business disruption/lost revenue: ~$1.2B
• Total disclosed impact: $2.87B in 2024
• Ransom payment: $22M (paid to prevent data release; attackers reportedly still leaked data)

Ongoing liability: The breach exposed protected health information (PHI) for an estimated 100M+ Americans — the largest healthcare data breach in US history. UnitedHealth faces class-action lawsuits, state investigations, federal regulatory actions under HIPAA, and Congressional scrutiny. Long-tail legal liability is not fully quantified.

Is UnitedHealth Group Profitable?

Yes — UnitedHealth reported net income of $22.4 billion on $400.3B in revenue in 2024 (net margin: 5.6%). Operating income was $30.4B (7.6% operating margin). Free cash flow was approximately $20–23B. The 2024 results were negatively affected by the $2.87B Change Healthcare cyberattack charges and elevated MCR (85.4% vs. 83–84% target); excluding these impacts, underlying profitability was materially stronger. In 2025, UnitedHealth’s stock fell sharply (from ~$600 to below $300) amid DOJ Medicare Advantage billing investigations and continued MCR pressure — the market pricing in significant execution risk, not a fundamental business collapse.

What to Watch

1. MCR normalization — the #1 financial catalyst — Every 100bps of MCR improvement on UHC’s premium base returns approximately $2.5B to annual operating income; management’s target of returning to 83.5–84.5% MCR requires: premium repricing to reflect elevated 2024 cost trends (happening in 2025 plan year pricing), CMS MA rate improvement (CMS sets MA rates annually), and Optum clinical integration reducing unnecessary utilization; the quarterly MCR disclosure is the single most important number in each UNH earnings release

2. DOJ Medicare Advantage investigation — Federal investigators have been examining UnitedHealth’s Medicare Advantage risk adjustment practices — specifically, whether UHC up-coded member diagnoses (adding conditions to medical records to increase the government capitation rate per member) inappropriately; MA risk adjustment fraud is a multi-billion dollar potential liability across the industry; UnitedHealth disclosed in late 2025 that DOJ had opened a formal investigation; the financial liability range could be $3–10B+ if the investigation results in settlements; watch for any new disclosures on investigation scope or settlement discussions

3. Optum growth and margin expansion — As Optum grows as a share of consolidated UNH revenue and earnings, the company’s overall margin profile should improve (Optum Insight’s ~20% operating margin vs. insurance’s ~4–5%); watch Optum Health’s capitated membership growth (the highest-quality, highest-margin revenue type in care delivery) and Optum Insight’s revenue cycle management recovery post-Change Healthcare; if Optum reaches 40%+ of consolidated operating income within 3 years, UNH’s valuation multiple should re-rate upward

4. Medicare Advantage rate environment — CMS sets MA payment rates annually (typically announced in April for the following plan year); rate increases above medical cost trend are margin-accretive; below-trend rate increases are the core reason MCR elevated in 2024; the 2026 and 2027 CMS final rate announcements will be the most important regulatory events affecting UNH’s medium-term earnings trajectory; any sustained CMS rate generosity after the 2024 squeeze would be a significant positive catalyst

5. GLP-1 drug cost integration — As Ozempic, Wegovy, Mounjaro, and Zepbound penetrate employer and MA plan formularies, the pharmacy cost per covered member increases substantially ($800–1,200/month vs. a few dollars for generic drugs); watch UNH’s pharmacy cost trend in Optum Rx and whether UHC begins covering GLP-1s for obesity (vs. only for diabetes); GLP-1 coverage decisions represent one of the largest binary cost events in UNH’s near-term cost structure; however, long-term, GLP-1 users who lose significant weight may have lower downstream medical costs (fewer cardiovascular events, reduced diabetes complications) — the net 5-year actuarial impact is the subject of active debate

6. Vertical integration antitrust scrutiny — The FTC, DOJ Antitrust Division, and multiple states have examined whether UnitedHealth’s ownership of insurance, care delivery, PBM, and data creates anticompetitive market conditions; the most extreme scenario — forced structural separation of UHC and Optum — would destroy the strategic rationale for UNH’s current valuation; even less extreme outcomes (PBM regulation, mandatory rebate pass-through, care delivery restrictions) could compress specific segment economics; any new antitrust filings, regulatory proposals, or enforcement actions targeting UNH’s vertical structure are material events

UnitedHealth Group (UNH) Financial Summary

UnitedHealth Group (NYSE: UNH) generated $400.3 billion in total revenue in 2024 (+7.7% YoY) — the world’s largest healthcare company — earning $22.4 billion in net income (5.6% net margin) and $30.4 billion in operating income (7.6% operating margin) through the vertically integrated combination of UnitedHealthcare health insurance (50M+ members, 29% Medicare Advantage market share) and Optum health services (90,000+ physicians, 1.6B prescriptions/year, healthcare data platform). Key challenges heading into 2026: MCR normalization from 85.4% toward the 83.5–84.5% target, DOJ Medicare Advantage billing investigation, Change Healthcare cyberattack legal tail, and GLP-1 drug cost integration. The strategic long-term thesis is that Optum’s growing share of earnings provides structural margin expansion as the highest-quality, highest-margin businesses grow fastest within the portfolio. For healthcare industry context, see the Healthcare Sector. For competitive comparison, review CVS Health and Elevance Health as the closest structural analogs.